Cargando…

异基因造血干细胞移植治疗阵发性睡眠性血红蛋白尿症(PNH)与PNH-再生障碍性贫血综合征疗效比较

OBJECTIVE: To compare the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for paroxysmal nocturnal hemoglobinuria (PNH) with paroxysmal nocturnal hemoglobinuria-aplastic anemia (PNH-AA) syndrome. METHODS: The outcomes of 46 patients who received allo-HSCT (16 PNH patients,...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342401/
https://www.ncbi.nlm.nih.gov/pubmed/31340619
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.06.005
_version_ 1783555473030512640
collection PubMed
description OBJECTIVE: To compare the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for paroxysmal nocturnal hemoglobinuria (PNH) with paroxysmal nocturnal hemoglobinuria-aplastic anemia (PNH-AA) syndrome. METHODS: The outcomes of 46 patients who received allo-HSCT (16 PNH patients, 30 PNH-AA patients) from July 10, 2007 to June 2, 2018 were analyzed retrospectively. The conditioning regimen was busulfan, cyclophosphoramide, and ATG in haploidentical donors and unrelated donors. Patients with matched sibling donors were treated with the fludarabine, cyclophosphamide, and ATG regimen. RESULTS: There were no differences of baseline data between the 2 groups except gender distribution and the numbers of haploidentical donor transplantation. The median values of absolute nucleated cell counts were 10.58 (3.83–13.83) ×10(8)/kg in the PNH group and 10.81 (3.96–33.40) ×10(8)/kg in the PNH-AA group (P=0.668). The median doses of CD34(+) cells infused were 5.00 (3.14–8.42) ×10(6)/kg and 3.57 (1.97–6.17) ×10(6)/kg (P=0.002), respectively. All patients obtained complete engraftment. The median time for myeloid engraftment were 11 (7–14) days in the PNH group and 12 (10–26) days in the PNH-AA group (P=0.003). The median time for platelet engraftment were 13 (11–16) days and 18 (12–75) days (P=0.002), respectively, after a median follow-up of 36 (4–132) months in the PNH group and 26 (4–75) months in the PNH-AA group (P=0.428). There were no differences of incidence rates of acute graft-versus-host disease (aGVHD), chronic GVHD and infection between PNH and PNH-AA groups (P>0.05). No patient occurred early death and relapse. The estimated 3-year overall survival (OS) of PNH and PNH-AA groups were (100.0±0.0) % and (85.7± 6.6) % (P=0.141), GVHD-free and failure-free survival (GFFS) were (100.0±0.0) %, (78.7±7.7) % (P=0.067). CONCLUSION: allo-HSCT is effective for patients with PNH and PNH-AA syndrome. The preliminary results indicate that myeloid and platelet engraftment in PNH group were faster than PNH-AA group. There were no differences in OS and GFFS between PNH group and PNH-AA group.
format Online
Article
Text
id pubmed-7342401
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73424012020-07-16 异基因造血干细胞移植治疗阵发性睡眠性血红蛋白尿症(PNH)与PNH-再生障碍性贫血综合征疗效比较 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To compare the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for paroxysmal nocturnal hemoglobinuria (PNH) with paroxysmal nocturnal hemoglobinuria-aplastic anemia (PNH-AA) syndrome. METHODS: The outcomes of 46 patients who received allo-HSCT (16 PNH patients, 30 PNH-AA patients) from July 10, 2007 to June 2, 2018 were analyzed retrospectively. The conditioning regimen was busulfan, cyclophosphoramide, and ATG in haploidentical donors and unrelated donors. Patients with matched sibling donors were treated with the fludarabine, cyclophosphamide, and ATG regimen. RESULTS: There were no differences of baseline data between the 2 groups except gender distribution and the numbers of haploidentical donor transplantation. The median values of absolute nucleated cell counts were 10.58 (3.83–13.83) ×10(8)/kg in the PNH group and 10.81 (3.96–33.40) ×10(8)/kg in the PNH-AA group (P=0.668). The median doses of CD34(+) cells infused were 5.00 (3.14–8.42) ×10(6)/kg and 3.57 (1.97–6.17) ×10(6)/kg (P=0.002), respectively. All patients obtained complete engraftment. The median time for myeloid engraftment were 11 (7–14) days in the PNH group and 12 (10–26) days in the PNH-AA group (P=0.003). The median time for platelet engraftment were 13 (11–16) days and 18 (12–75) days (P=0.002), respectively, after a median follow-up of 36 (4–132) months in the PNH group and 26 (4–75) months in the PNH-AA group (P=0.428). There were no differences of incidence rates of acute graft-versus-host disease (aGVHD), chronic GVHD and infection between PNH and PNH-AA groups (P>0.05). No patient occurred early death and relapse. The estimated 3-year overall survival (OS) of PNH and PNH-AA groups were (100.0±0.0) % and (85.7± 6.6) % (P=0.141), GVHD-free and failure-free survival (GFFS) were (100.0±0.0) %, (78.7±7.7) % (P=0.067). CONCLUSION: allo-HSCT is effective for patients with PNH and PNH-AA syndrome. The preliminary results indicate that myeloid and platelet engraftment in PNH group were faster than PNH-AA group. There were no differences in OS and GFFS between PNH group and PNH-AA group. Editorial office of Chinese Journal of Hematology 2019-06 /pmc/articles/PMC7342401/ /pubmed/31340619 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.06.005 Text en 2019年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
异基因造血干细胞移植治疗阵发性睡眠性血红蛋白尿症(PNH)与PNH-再生障碍性贫血综合征疗效比较
title 异基因造血干细胞移植治疗阵发性睡眠性血红蛋白尿症(PNH)与PNH-再生障碍性贫血综合征疗效比较
title_full 异基因造血干细胞移植治疗阵发性睡眠性血红蛋白尿症(PNH)与PNH-再生障碍性贫血综合征疗效比较
title_fullStr 异基因造血干细胞移植治疗阵发性睡眠性血红蛋白尿症(PNH)与PNH-再生障碍性贫血综合征疗效比较
title_full_unstemmed 异基因造血干细胞移植治疗阵发性睡眠性血红蛋白尿症(PNH)与PNH-再生障碍性贫血综合征疗效比较
title_short 异基因造血干细胞移植治疗阵发性睡眠性血红蛋白尿症(PNH)与PNH-再生障碍性贫血综合征疗效比较
title_sort 异基因造血干细胞移植治疗阵发性睡眠性血红蛋白尿症(pnh)与pnh-再生障碍性贫血综合征疗效比较
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342401/
https://www.ncbi.nlm.nih.gov/pubmed/31340619
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.06.005
work_keys_str_mv AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào
AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào
AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào
AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào
AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào
AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào
AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào
AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào
AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào
AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào
AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào
AT yìjīyīnzàoxuègànxìbāoyízhízhìliáozhènfāxìngshuìmiánxìngxuèhóngdànbáiniàozhèngpnhyǔpnhzàishēngzhàngàixìngpínxuèzōnghézhēngliáoxiàobǐjiào